Top Page
Century Therapeutics
(NASDAQ:IPSC)
Century Therapeutics (IPSC) vs. SPDR S&P 500 ETF (SPY)
Century Therapeutics Business Overview & Revenue Model
Century Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 113.34M | 6.59M | 2.23M | 5.20M | 0.00 | 0.00 |
| Gross Profit | 107.01M | 6.59M | 2.23M | 5.20M | -4.58M | -1.75M |
| EBITDA | -14.21M | -111.47M | -121.21M | -121.20M | -89.92M | -51.44M |
| Net Income | -26.48M | -126.57M | -136.67M | -130.93M | -95.82M | -53.58M |
Balance Sheet | ||||||
| Total Assets | 244.72M | 353.22M | 360.69M | 486.54M | 437.38M | 106.78M |
| Cash, Cash Equivalents and Short-Term Investments | 132.75M | 189.29M | 172.74M | 315.50M | 222.88M | 75.75M |
| Total Debt | 44.96M | 53.83M | 48.17M | 49.41M | 25.12M | 21.55M |
| Total Liabilities | 68.37M | 191.85M | 175.94M | 183.81M | 41.14M | 213.19M |
| Stockholders Equity | 176.35M | 161.36M | 184.75M | 302.74M | 396.24M | -106.41M |
Cash Flow | ||||||
| Free Cash Flow | -112.69M | -110.29M | -102.08M | -16.55M | -133.97M | -51.09M |
| Operating Cash Flow | -112.02M | -110.14M | -88.35M | 14.05M | -89.00M | -41.27M |
| Investing Cash Flow | 115.75M | 47.48M | 61.13M | -13.13M | -298.34M | -22.76M |
| Financing Cash Flow | -482.00K | 74.56M | -9.72M | 27.16M | 417.77M | 47.69M |
Century Therapeutics Technical Analysis
Century Therapeutics Risk Analysis
Century Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $166.07M | -6.11 | -14.23% | ― | 4121.12% | 83.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $35.23M | -1.80 | -104.58% | ― | ― | 1.18% | |
47 Neutral | $34.77M | -0.16 | ― | ― | -66.96% | 71.83% | |
45 Neutral | $36.19M | -1.05 | -133.09% | ― | 11.11% | 20.65% | |
44 Neutral | $13.40M | -0.27 | -405.03% | ― | ― | 49.43% | |
40 Underperform | $12.97M | -0.56 | -526.36% | ― | ― | -2.46% |
Century Therapeutics Corporate Events
On January 22, 2026, Century Therapeutics, Inc. held a virtual special meeting of stockholders at which shareholders approved an amendment to the company’s certificate of incorporation authorizing a potential reverse stock split of its common shares at a ratio between 1-for-5 and 1-for-30, subject to the board’s discretion. On the same day, the company received notice from Nasdaq that it had regained compliance with the exchange’s minimum $1.00 bid price requirement and all other continued listing standards, leading Century Therapeutics to announce it does not intend to implement the reverse stock split, a decision that stabilizes its listing status and avoids the immediate dilutionary and structural impacts such a split might have had on existing shareholders.
The most recent analyst rating on (IPSC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
On January 12, 2026, Century Therapeutics updated an investor slide presentation detailing progress across its cell therapy pipeline and plans to unlock the value of its programs in Type 1 diabetes and autoimmune disease. The company highlighted that CNTY-813 and CNTY-308, both incorporating its Allo-Evasion 5.0 technology for enhanced immune evasion and persistence, are in IND-enabling studies with CNTY-813 targeted for an investigational filing in 2026 and early clinical data expected in 2027, while CNTY-308 is anticipated to enter the clinic in 2026. Century also reported that patient enrollment is ongoing in the Phase 1/2 CARAMEL investigator-sponsored trial of CNTY-101 in autoimmune disease, and said its cash runway extends beyond planned key clinical milestones, underscoring its capacity to advance multiple high-impact programs in parallel and strengthen its position as a leader in immune-evasive allogeneic cell therapies.
The most recent analyst rating on (IPSC) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
On January 7, 2026, Century Therapeutics entered into a securities purchase agreement with institutional investors for an oversubscribed private placement expected to close on January 9, 2026, raising approximately $135 million in gross proceeds through the sale of about 117.4 million shares of common stock (or pre-funded warrants) and accompanying warrants priced in line with Nasdaq “Minimum Price” requirements. The financing, led by new investor TCGX with participation from RA Capital, Commodore Capital, Deep Track Capital, RTW Investments, Venrock Healthcare Capital Partners, the T1D Fund and others, strengthens Century’s balance sheet to support development of its lead iPSC-derived beta islet cell therapy candidate CNTY-813 for Type 1 diabetes, including funding toward an investigational new drug filing planned for 2026 and initial clinical data expected in 2027, and could deliver an additional roughly $153 million if all warrants are exercised, while also committing the company to register the resale of the issued securities under a new registration rights agreement.
The most recent analyst rating on (IPSC) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
On December 18, 2025, Century Therapeutics, Inc. announced that board member Carlo Rizzuto, Ph.D., resigned from its board of directors, effective the same day. The company emphasized that Rizzuto’s departure did not arise from any disagreement over its operations, policies, or practices, and publicly expressed appreciation for his distinguished service and lasting contributions to the organization.
The most recent analyst rating on (IPSC) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
On December 12, 2025, Century Therapeutics updated its slide presentation to reflect advancements in its cell therapy pipeline, which will be used in investor meetings. The company is progressing with its Allo-Evasion technology, with key programs like CNTY-101 in Phase 1/2 trials for autoimmune diseases and CNTY-813 in preclinical development for Type 1 Diabetes. The announcement highlights the company’s strategic focus on executing high-impact programs and extending its cash runway beyond key clinical milestones anticipated in late 2027.
The most recent analyst rating on (IPSC) stock is a Hold with a $0.56 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
On December 9, 2025, Century Therapeutics announced the expansion of its Board of Directors from six to eight members, appointing Dr. Martin Murphy and Dr. Han Lee as new directors. Dr. Murphy, with extensive experience in life science investment and company creation, will serve on the Compensation and Nominating and Corporate Governance Committees, while Dr. Lee, with a strong background in capital formation and corporate development, will join the Audit and Compensation Committees. This strategic move is expected to enhance Century’s efforts to advance its iPSC-derived cell therapy programs, including its lead candidate CNTY-813 for type 1 diabetes, potentially delivering significant value to patients and stakeholders.
The most recent analyst rating on (IPSC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
On November 13, 2025, Century Therapeutics announced the launch of its first program for Type 1 diabetes, CNTY-813, with plans to initiate IND-enabling studies by the end of 2025 and submit an IND in 2026. The company is also advancing CNTY-308 through IND-enabling studies for B-cell-mediated diseases, targeting clinical study initiation in 2026. Additionally, Century reported a net loss of $34.4 million for the third quarter of 2025, with a cash runway estimated to extend into the fourth quarter of 2027, reflecting a strategic focus on high-impact therapeutic areas and resource allocation.
The most recent analyst rating on (IPSC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.